Targeting NF-κB modulation and its downstream regulatory molecules in the PVN provides a roadmap for tackling possible therapeutic strategies to the improvement of central neural control of sympathetic nerve activity in HF. This evidence concerns the gene NFKB1 and hydrops fetalis.